



Published in final edited form as:

Curr Opin Ophthalmol. 2015 March ; 26(2): 78–81. doi:10.1097/ICU.0000000000000135.

Exfoliation syndrome: a disease with an environmental component

Samantha Dewundara^a, Louis R. Pasquale^{a,b,c}

^aDepartment of Ophthalmology, Brigham and Women's Hospital, Boston, Massachusetts, USA

^bHarvard Medical School, Massachusetts Eye and Ear, Brigham and Women's Hospital, Boston, Massachusetts, USA

^cDivision of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA

Abstract

Purpose of review—Exfoliation syndrome (XFS), the most common cause of secondary open angle glaucoma, is associated with significant ocular morbidity. Recent studies have pointed toward environmental components that may alter the risk of XFS development. This review focuses on the recent studies elucidating the role of environmental factors that play a role in the development of exfoliation syndrome.

Recent findings—In XFS, aberrant microfibril formation emanating from the cell-extracellular matrix interface admixes with other macromolecules and is cross-linked by lysyl oxidase like 1 (LOXL1) activity. A common gene variant in the LOXL1 enzyme, an enzyme critical for enhancing the tensile strength of collagen and elastin in extracellular matrices, has been found in approximately 90% of XFS cases. However, approximately 80% of controls also have disease-associated *LOXL1* gene variants. These findings point toward other nongenetic factors influencing the development of XFS. Increasing latitude, solar radiation, climatic variables and dietary factors such as high coffee consumption and low dietary folate intake are among the nongenetic factors associated with increased risk of XFS.

Summary—A greater understanding of the environmental components associated with XFS may lead to lifestyle preventive strategies to ameliorate disease burden.

Keywords

coffee consumption; dietary folate; environmental factors; exfoliation syndrome; latitude effect; solar exposure

Correspondence to Louis R. Pasquale, MD, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. Tel: +1 617 573 3674; fax: +1 617 573 3707; Louis_Pasquale@meei.harvard.edu.

Conflicts of interest

There are no conflicts of interest.

INTRODUCTION

Exfoliation syndrome (XFS), the most common cause of secondary open-angle glaucoma [1], is a progressive disease characterized by accumulation of fibrillar extracellular deposits on various anterior segment ocular tissues [2]. XFS is associated with significant ocular morbidity and can lead to multiple ocular sequelae including glaucomatous optic neuropathy secondary to elevated intraocular pressure [3], late-onset spontaneous intraocular lens subluxation [4] and retinal vein occlusion [5-9]. XFS leads to increased cataract formation [10-12] and is associated with increased cataract surgery complications, [13-16] in part due to compromised zonular stability [17,18].

The underlying mechanism of XFS is believed to involve aberrant extracellular matrix metabolism [19] yielding an abnormal aggregation of elastic fiber components [20]. This concept was further supported when the common gene variants in lysyl oxidase-like 1 (LOXL1) enzyme, an enzyme pivotal in enhancing the tensile strength of collagen and elastin in extracellular matrices [21], were found in 99% of XFS cases in Scandinavian populations from Iceland and Sweden [22]. However, up to 80% of controls also had disease-associated *LOXL1* gene variants [22-26]. Similar findings were observed in cases and controls from Australia where disease prevalence is only approximately 1% [27,28]. These findings suggest that other factors in addition to genetics contribute to XFS.

THE LATITUDE EFFECT

The estimates of XFS prevalence tend to increase as a function of latitude in the northern hemisphere. Although certain exceptions exist [29], prior point prevalence studies (Table 1) demonstrate this trend with evidence of hyperendemicity in Northern Europe. This trend holds true in the continental USA using multivariable analyses in two separate study samples [40,41]. Furthermore, Kang *et al.* [41] found that lifetime residence in the middle or lower tier of the USA was associated with reduced risk of XFS compared with lifetime residence in the northern US tier. In this study, the association with latitude was the same in White and non-White cases, indicating that a trend toward genetically predisposed Northern Europeans populating northern tier states does not explain these results [41]. Environmental factors such as climatic variables and solar exposure may be responsible for these findings.

CLIMATIC FACTORS

Colder temperatures in the summer and winter months were found to be independent risk factors for development of XFS [40]. In fact, many of the highest XFS prevalences are from countries with cold mean temperatures such as Iceland, Norway and Sweden. Perhaps the extracellular deposits of XFS represent a precipitation reaction [42] that is more susceptible to develop at colder temperatures. Although the temperature of visceral organs may be close to core body temperature regardless of the ambient temperature, the relatively avascular ocular anterior segment may be more likely to experience a temperature drop in colder environments [43].

SOLAR EXPOSURE

The relative immunity of Arctic-dwelling Inuit people to develop XFS [44] suggests that other climatic factors contribute to the disease. The idea that solar exposure might contribute to XFS was suggested in 1979 based on a review of the ocular characteristics found in an Australian Aboriginal population and the increased prevalence among those who worked with livestock [45]. Similar findings from rural India confirmed that XFS was more common in those participating in outdoor occupations [46]. Recently, Kang *et al.* [41] found that greater time spent outdoors during the summer months from high school to age 24 was independently associated with greater risk of incident XFS, supporting a possible causal relationship of early exposure to outdoor climatic factors on XFS risk. Furthermore, there have been strong associations between XFS and other ultraviolet (UV) associated ocular diseases such as climatic droplet keratopathy [47]. In-vitro studies of human Tenon's capsule fibroblasts provide some support for a role of UV light in XFS cause. UV-light exposure has been found to upregulate the expression of LOXL1 and major elastic fiber proteins found in the exfoliation extracellular deposits [48].

Most recently, Pasquale *et al.* [49[■]] found that more time spent outdoors in the summer over a lifetime was associated with XFS in case-control groups from the USA and Israel. Furthermore, work over reflective surfaces such as water or snow in the USA was associated with increased odds of XFS [49[■]]. Interestingly, Sydenham *et al.* [50] found that ambient UV exposure does not fully account for ocular solar exposure and it is known that snow reflects as much as 80% of UV-B during midday [51]. These findings provide insight into the data reported by Pasquale *et al.* [49[■]], suggesting that ocular exposure to light from reflective surfaces may be an important UV source in the pathogenesis of XFS.

ELEVATED HOMOCYSTEINE LEVELS, DIETARY FOLATE AND COFFEE CONSUMPTION

Elevated homocysteine may increase exfoliation material (XFM) formation by contributing to vascular damage [52], oxidative stress [53,54] and changes in the extracellular matrix [19]. Homocysteine levels are higher in the serum [55-57], aqueous humor [58] and tear [59] samples of XFS patients compared with controls. The synthesis of methionine from homocysteine requires folic acid enzymes and so a deficiency of folic acid leads to elevated homocysteine plasma levels [60]. Low serum folate levels are associated with increased risk of XFS [61]. Kang *et al.* [62[■]] found lower risk of XFS with higher folate intake but not with vitamin B6 or vitamin B12 intake. Meanwhile, the Reykjavik Eye study showed that higher consumption of fruits and vegetables was associated with a reduced risk of XFS [63]. Interestingly, fruit and vegetables serve as a major source of dietary folate.

Coffee consumption may be yet another dietary factor that alters XFS. In a prospective study performed in the USA, heavy coffee consumption is associated with increased risk of XFS [64]. A possible etiologic factor explaining this finding may be that coffee consumption produces increased homocysteine levels [65]. The exact mechanism by which homocysteine enhances XFM formation remains unclear but may rely on the complex interaction between extracellular matrix metalloproteinase regulation [66].

CONCLUSION

LOXL1 genotype markers have served as the springboard to investigate environmental factors associated with XFS. Environmental factors may alter LOXL1 activity, which in turn increases the predisposition of individuals already at risk to accumulate XFM. Climatic variables operative at higher residential latitude are environmental factors that appear to contribute to XFS. Furthermore, dietary factors such as folate intake and coffee consumption have been found to alter the risk of XFS, possibly by affecting homocysteine levels. Further studies are needed to elucidate the exact mechanism by which homocysteine alters the development of XFM. These findings suggest that alterations in environmental factors could lead to disease modification in persons who may be genetically predisposed to develop XFS.

Acknowledgments

Financial support and sponsorship

The Arthur Ashley Foundation, grant # EY020928 from the National Institutes of Health, and a Harvard Medical School Distinguished Ophthalmology Scholar Award supported this work.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

■ of special interest

■ ■ of outstanding interest

1. Ritch R Exfoliation syndrome—the most common identifiable cause of open-angle glaucoma. *J Glaucoma* 1994; 3:176–177. [PubMed: 19920577]
2. Lindberg JG. Clinical investigations of depigmentation of the pupillary border and translucency of the iris in cases of senile cataract and in normal eyes in elderly persons. *Acta Ophthalmol Supp* 1989; 19:1–96.
3. Ritch R, Schlotzer-Schrehardt U, Konstas AG. Why is glaucoma associated with exfoliation syndrome? *Prog Retin Eye Res* 2003; 22:253–275. [PubMed: 12852486]
4. Davis D, Brubaker J, Espandar L, et al. Late in-the-bag spontaneous intraocular lens dislocation: evaluation of 86 consecutive cases. *Ophthalmology* 2009; 116:664–670. [PubMed: 19344819]
5. Ritch R, Prata TS, de Moraes CG, et al. Association of exfoliation syndrome and central retinal vein occlusion: an ultrastructural analysis. *Acta Ophthalmol* 2010; 88:91–95. [PubMed: 19725816]
6. Prata TS, Rozenbaum I, de Moraes CG, et al. Retinal vascular occlusions occur more frequently in the more affected eye in exfoliation syndrome. *Eye (Lond)* 2010; 24:658–662. [PubMed: 19557023]
7. Cursiefen C, Hammer T, Kuchle M, et al. Pseudoexfoliation syndrome in eyes with ischemic central retinal vein occlusion. A histopathologic and electron microscopic study. *Acta Ophthalmol Scand* 2001; 79:476–478. [PubMed: 11594982]
8. Gillies WE, Brooks AM. Central retinal vein occlusion in pseudoexfoliation of the lens capsule. *Clin Experiment Ophthalmol* 2002; 30:176–187. [PubMed: 12010209]
9. Saatci OA, Ferliel ST, Ferliel M, et al. Pseudoexfoliation and glaucoma in eyes with retinal vein occlusion. *Int Ophthalmol* 1999; 23:75–78. [PubMed: 11196123]
10. Puska P, Tarkkanen A. Exfoliation syndrome as a risk factor for cataract development: five-year follow-up of lens opacities in exfoliation syndrome. *J Cataract Refract Surg* 2001; 27:1992–1998. [PubMed: 11738916]
11. Fama F, Castagna I, Salmeri G. Influence of pseudoexfoliation syndrome on human lens transparency. *Ann Ophthalmol* 1993; 25:440–441. [PubMed: 8129325]

12. Arnarsson A, Sasaki H, Jonasson F. Twelve-year incidence of exfoliation syndrome in the Reykjavik Eye Study. *Acta Ophthalmol* 2013; 91:157–162. [PubMed: 22268376]
13. Naumann GO. Exfoliation syndrome as a risk factor for vitreous loss in extracapsular cataract surgery (preliminary report). Erlanger-Augenblatter-Group. *Acta Ophthalmol Suppl* 1988; 184:129–131. [PubMed: 2853911]
14. Scorolli L, Campos EC, Bassein L, Meduri RA. Pseudoexfoliation syndrome: a cohort study on intraoperative complications in cataract surgery. *Ophthalmologica* 1998; 212:278–280. [PubMed: 9672219]
15. Shingleton BJ, Heltzer J, O'Donoghue MW. Outcomes of phacoemulsification in patients with and without pseudoexfoliation syndrome. *J Cataract Refract Surg* 2003; 29:1080–1086. [PubMed: 12842671]
16. Abela-Formanek C, Amon M, Schauersberger J, et al. Uveal and capsular biocompatibility of 2 foldable acrylic intraocular lenses in patients with uveitis or pseudoexfoliation syndrome: comparison to a control group. *J Cataract Refract Surg* 2002; 28:1160–1172. [PubMed: 12106724]
17. Skuta GL, Parrish RK II, Hodapp E, et al. Zonular dialysis during extracapsular cataract extraction in pseudoexfoliation syndrome. *Arch Ophthalmol* 1987; 105:632–634. [PubMed: 3619736]
18. Schlötzer-Schrehardt U, Naumann GO. A histopathologic study of zonular instability in pseudoexfoliation syndrome. *Am J Ophthalmol* 1994; 118:730–743. [PubMed: 7977599]
19. Eagle RC Jr, Font RL, Fine BS. The basement membrane exfoliation syndrome. *Arch Ophthalmol* 1979; 97:510–515. [PubMed: 420639]
20. Schlotzer-Schrehardt U. Molecular pathology of pseudoexfoliation syndrome/glaucoma: new insights from LOXL1 gene associations. *Exp Eye Res* 2009; 88:776–785.
21. Xiao Q, Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. *Cancer Microenviron* 2012; 5:261–273. [PubMed: 22528876]
22. Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. *Science* 2007; 317:1397–1400. [PubMed: 17690259]
23. Whigham BT, Allingham RR. Review: the role of LOXL1 in exfoliation syndrome/glaucoma. *Saudi J Ophthalmol* 2011; 25:347–352. [PubMed: 23960948]
24. Jaimes M, Rivera-Parra D, Miranda-Duarte A, et al. Prevalence of high risk alleles in the LOXL1 gene and its association with pseudoexfoliation syndrome and exfoliation glaucoma in a Latin American population. *Ophthalmic Genet* 2012; 33:12–17. [PubMed: 21970694]
25. Michael S, Khan MI, Akhtar F, et al. Role of lysyl oxidase-like 1 gene polymorphisms in Pakistani patients with pseudoexfoliative glaucoma. *Mol Vis* 2012; 18:1040–1044. [PubMed: 22605916]
26. Park do Y, Won HH, Cho HK, Kee C. Evaluation of lysyl oxidase-like 1 gene polymorphisms in pseudoexfoliation syndrome in a Korean population. *Mol Vis* 2013; 19:448–453. [PubMed: 23441117]
27. Hewitt AW, Sharma S, Burdon KP, et al. Ancestral LOXL1 variants are associated with pseudoexfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people. *Hum Mole Genet* 2008; 17:710–716.
28. McCarty CA, Taylor HR. Pseudoexfoliation syndrome in Australian adults. *Am J Ophthalmol* 2000; 129:629–633. [PubMed: 10844055]
29. Young AL, Tang WW, Lam DS. The prevalence of pseudoexfoliation syndrome in Chinese people. *Br J Ophthalmol* 2004; 88:193–195. [PubMed: 14736771]
30. Astrom S, Stenlund H, Linden C. Incidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden: II results after 2 years of follow up. *Acta Ophthalmol Scand* 2007; 85:832–837.
31. Ringvold A, Blika S, Elsås T, et al. The prevalence of pseudoexfoliation in three separate municipalities of Middle-Norway. *Acta Ophthalmol Suppl* 1987; 182:17–20. [PubMed: 2837055]
32. Arnarsson A, Damji KF, Sverrisson T, et al. Pseudoexfoliation in the Reykjavik Eye Study: prevalence and related ophthalmological variables. *Acta Ophthalmol Scand* 2007; 85:822–827. [PubMed: 18028119]
33. Forsman E, Cantor RM, Lu A, et al. Exfoliation syndrome: prevalence and inheritance in a subisolate of the Finnish population. *Acta Ophthalmol Scand* 2007; 85:500–507. [PubMed: 17655611]

34. Topouzis F, Wilson MR, Harris A, et al. Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. *Am J Ophthalmol* 2007; 144:511–519. [PubMed: 17893012]
35. Rao RQ, Arain TM, Ahad MA. The prevalence of pseudoexfoliation syndrome in Pakistan. Hospital based study. *BMC Ophthalmol* 2006; 6:27. [PubMed: 16792800]
36. Shazly TA, Farrag AN, Kamel A, Al-Hussaini AK. Prevalence of pseudoexfoliation syndrome and pseudoexfoliation glaucoma in Upper Egypt. *BMC Ophthalmol* 2011; 11:18. [PubMed: 21707986]
37. Olawoyee OO, Ashaye AO, Tenv GG, et al. Exfoliation syndrome in Nigeria. *Middle East Afr J Ophthalmol* 2012; 19:402–405. [PubMed: 23248543]
38. Rudkin AK, Edussuriya K, Sennanayake S, et al. Prevalence of exfoliation syndrome in central Sri Lanka: the Kandy Eye Study. *Br J Ophthalmol* 2008; 92:1595–1598. [PubMed: 18927228]
39. McCarty CA, Taylor HR. Pseudoexfoliation syndrome in Australian adults. *Am J Ophthalmol* 2000; 129:629–633. [PubMed: 10844055]
40. Stein JD, Pasquale LR, Talwar N, et al. Geographic and climatic factors associated with exfoliation syndrome. *Arch Ophthalmol* 2011; 129:1053–1060. [PubMed: 21825188]
41. Kang JH, Loomis S, Wiggs JL, et al. Demographic and geographic features of exfoliation glaucoma in 2 United States-based prospective cohorts. *Ophthalmology* 2012; 119:27–35. [PubMed: 21982415]
42. Lee RK. The molecular pathophysiology of pseudoexfoliation glaucoma. *Curr Opin Ophthalmol* 2008; 19:95–101. [PubMed: 18301281]
43. Al-Ghadyan AA, Cotlier E. Rise in lens temperature on exposure to sunlight or high ambient temperature. *Br J Ophthalmol* 1986; 70:421–426. [PubMed: 3718905]
44. Foriis H, Luukka H. Pseudoexfoliation of the anterior capsule of the lens in Lapps and Eskimos. *Can J Ophthalmol* 1973; 8:274–277. [PubMed: 4707213]
45. Taylor HR. The prevalence of corneal disease and cataracts in Australian aborigines in Northwestern Australia. *Aust J Ophthalmol* 1980; 8:289–301. [PubMed: 7224984]
46. Thomas R, Nirmalan PK, Krishnaiah S. Pseudoexfoliation in southern India: the Andhra Pradesh Eye Disease Study. *Invest Ophthalmol Vis Sci* 2005; 46:1170–1176. [PubMed: 15790875]
47. Resnikoff S, Filliard G, Dell’ Aquila B. Climatic droplet keratopathy, exfoliation syndrome, and cataract. *Br J Ophthalmol* 1991; 75:734–736. [PubMed: 1768663]
48. Zenkel M, Krysta A, Pasutto F, et al. Regulation of lysyl oxidase-like 1 (LOXL1) and elastin-related genes by pathogenic factors associated with pseudoexfoliation syndrome. *Invest Ophthalmol Vis Sci* 2011; 52:8488–8495. [PubMed: 21948647]
49. Pasquale LR, Jiواني AZ, Zehavi-Dorin T, et al. Solar exposure and residential geographic history in relation to exfoliation syndrome in the United States and Israel. *JAM Ophthalmol* 2014; 132:1439–1445. This clinic-based case-control study in the United States and Israel found lifetime outdoor activities may contribute to XFS. This study suggests that ocular exposure to light from reflective surfaces may be an important type of environmental exposure in XFS cause.
50. Sydenham MM, Collins MJ, Hirst LW. Measurement of ultraviolet radiation at the surface of the eye. *Invest Ophthalmol Vis Sci* 1997; 38:1485–1492. [PubMed: 9224276]
51. Sliney DH. Physical factors in cataractogenesis: ambient ultraviolet radiation and temperature. *Invest Ophthalmol Vis Sci* 1986; 27:781–790. [PubMed: 3700027]
52. Brooks AM, Gillies WE. The development of microvascular changes in the iris in pseudoexfoliation of the lens capsule. *Ophthalmology* 1987; 94:1090–1097. [PubMed: 2446230]
53. Gartaganis SP, Patsoukis NE, Mikolopoulos DK, Georgiou CD. Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndrome. *Eye (Lond)* 2007; 21:1406–1411. [PubMed: 17001325]
54. Yagci R, Gurel A, Ersoz I, et al. Oxidative stress and protein oxidation in pseudoexfoliation syndrome. *Curr Eye Res* 2006; 31:1029–1032. [PubMed: 17169841]
55. Vessani RM, Ritch R, Liebmann JM, Jofe M. Plasma homocysteine is elevated in patients with exfoliation syndrome. *Am J Ophthalmol* 2003; 136:41–46. [PubMed: 12834668]
56. Puustjarvi T, Blomster H, Kontkanen M, et al. Plasma and aqueous humour levels of homocysteine in exfoliation syndrome. *Graefes Arch Clin Exp Ophthalmol* 2004; 42:749–754. [PubMed: 15052489]

57. Altintas O, Maral H, Yuksel N, et al. Homocysteine and nitric oxide levels in plasma of patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma, and primary open-angle glaucoma. *Graefes Arch Clin Exp Ophthalmol* 2005; 243:677–683. [PubMed: 15688159]
58. Bleich S, Roedl J, VonAhsen N, et al. Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma. *Am J Ophthalmol* 2004; 138:162–164. [PubMed: 15234308]
59. Roedl J, Bleich S, Reulbach U, et al. Homocysteine in tear fluid of patients with pseudoexfoliation glaucoma. *J Glaucoma* 2007; 16:234–239. [PubMed: 17473737]
60. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. *Euro J Pediatr* 1998; 157:40–44.
61. Xu F, Zhang L, Li M. Plasma homocysteine, serum folic acid, serum vitamin B12, serum vitamin B6, MTHFR and risk of pseudoexfoliation glaucoma: a meta-analysis. *Graefes Arch Clin Exp Ophthalmol* 2012; 250:1067–1074. [PubMed: 22134713]
62. Kang JH, Loomis SJ, Wiggs JL, et al. A prospective study of folate, vitamin B6, and vitamin B12 intake in relation to exfoliation glaucoma or suspected exfoliation glaucoma. *JAMA Ophthalmol* 2014; 132:549–559. [PubMed: 24699833] This prospective cohort study found a suggestive trend of lower risk of exfoliation glaucoma or suspected exfoliation glaucoma with higher folate intake. This supports a possible role for homocysteine in the development exfoliation glaucoma/suspected exfoliation glaucoma.
63. Amarsson AM. Epidemiology of exfoliation syndrome in the Reykjavik Eye Study. *Acta Ophthalmol* 2009; 87:1–17.
64. Pasquale LR, Wiggs JL, Willett WC, Kang JH. The relationship between caffeine and coffee consumption and exfoliation glaucoma or glaucoma suspect: a prospective study in two cohorts. *Invest Ophthalmol Vis Sci* 2012; 53:6427–6433. [PubMed: 22918628]
65. Urgert R, van Vliet T, Zock PL, Katan MB. Heavy coffee consumption and plasma homocysteine: a randomized controlled trial in healthy volunteers. *Am J Clin Nutr* 2000; 72:1107–1110. [PubMed: 11063436]
66. Bescond A, Augier T, Chareyre C, et al. Influence of homocysteine on matrix metalloproteinase-2 activation and activity. *Biochem Biophys Res Commun* 1999; 263:498–503. [PubMed: 10491321]

KEY POINTS

- Environmental factors may play a role in the development of XFS.
- XFS prevalence tends to increase as a function of latitude.
- Ocular exposure to light from reflective surfaces may be an important environmental factor in the pathogenesis of XFS.
- Dietary factors such as folate intake and coffee consumption may increase the risk of XFS.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Published exfoliation syndrome prevalence

Country	Disease prevalence			Age range (years)	Latitude
	% Men	% Women	% total		
Sweden [30]	17.0	31.0		70-79	64.4°N
Norway [31]	16.9 total			64+	64.3°N
Iceland [32]	13.4	21.6		70-79	64.1°N
Finland [33]	17.0	31.0		70-79	59.6°N
Greece [34]	10.9	13.2		60+	39.0°N
Pakistan [35]	13.0 total			70+	29.4°N
Upper Egypt [36]	4.3	4.1		70-79	25.7°N
Nigeria [37]	2.7 total			30+	7.3°N
Sri Lanka [38]	3.8 total			70+	7.0°N
Australia [39]	2.9	1.7		70-79	37.0°S